Latest Conference Articles

Weekly dupilumab 300 mg versus placebo demonstrated statistically significant, clinically meaningful improvements in histologic and endoscopic outcomes and symptoms in adults and adolescents with eosinophilic esophagitis.

The approval of risankizumab represents the first IL-23 approved for IBD.

With dupilumab already available and JAK inhibitors on the way, clinicians have a bevy of treatments designated for pediatric patients.

Falloon presented new data at ACG 2022 on identifying biomarkers for pouch inflammation.

Patients with NAFLD were more likely to have comorbidities, including diabetes, hypertension, chronic respiratory disease, hypothyroidism, chronic kidney disease, sleep apnea, and hyperlipidemia.

A 30 mg dose of upadacitinib led to a 1 month longer clinical remission and approximately 20% of patients had less severe disease at 52 weeks, when compared with a 15 mg dose for patients with active ulcerative colitis.

The rate of serious infections was 5.9 events per 100 person-years in the placebo group, compared to 5.0 events in the upadacitinib 15 mg cohort and 3.2 upadacitinib 30 mg group.

In data presented during ACG, investigators found patients with malnutrition and CDI had higher mortality and increased hospitals costs compared to those without malnutrition.

In consideration of emerging JAK inhibitor options, and the current prescribing availability of baricitinib.

New open-label extension data support the long-term use of the systemic therapy in patients with moderate-to-severe disease.

The study results are consistent with previous meta-analyses that show the efficacy of FMT in patients with IBD compared to placebo.

Bezlotoxumab is a fully humanized monoclonal antibody approved by the US Food and Drug Administration in 2017 for the prevention of recurrent CDI.

Brett King, MD, PhD, explains the altered screening and care strategies for patients following baricitinib's approval.

Real-world analysis comparing systemic therapies show dupilumab better improves EASI and quality of life among affected children.

Brett King, MD, PhD, discusses the newly available JAK inhibitor—the first systemic therapy approved for the hair-loss condition.

Data from the ongoing TARGET-DERM AM observational study show patients with more exposed disease have generally worse severity and challenges linked to quality of life.

The JAK inhibitor received FDA approval for vitiligo this summer. Investigator now see it as a potent non-steroidal option for eczema.

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.

A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.

Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.

Data from NORD Breakthrough Summit 2022 support the need for exacerbation prevention among patients with bronchiectasis, a rare chronic condition.

Dr. Chopra elaborated on his Pri-Med Midwest 2022 presentation regarding the future of advances in medicine, specifically highlighting artificial intelligence, gut microbiome research, and gene editing.